Eric Rovner to Urinary Bladder, Overactive
This is a "connection" page, showing publications Eric Rovner has written about Urinary Bladder, Overactive.
Connection Strength
7.712
-
Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020 02; 39(2):744-753.
Score: 0.665
-
One-year results with selective bladder denervation in women with refractory overactive bladder. Neurourol Urodyn. 2019 11; 38(8):2178-2184.
Score: 0.643
-
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology. Contemp Clin Trials. 2018 07; 70:83-87.
Score: 0.592
-
Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study. Low Urin Tract Symptoms. 2018 Sep; 10(3):221-230.
Score: 0.554
-
Lower urinary tract symptoms in women: epidemiology, diagnosis, and management. Curr Opin Urol. 2016 07; 26(4):328-33.
Score: 0.520
-
Chapter 6: Practical aspects of administration of onabotulinumtoxinA. Neurourol Urodyn. 2014 Jul; 33 Suppl 3:S32-7.
Score: 0.453
-
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013 Nov; 32(8):1109-15.
Score: 0.411
-
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011 Apr; 30(4):556-62.
Score: 0.359
-
Urodynamics in the evaluation of overactive bladder. Curr Urol Rep. 2010 Sep; 11(5):343-7.
Score: 0.347
-
Frequently asked questions in the evaluation and management of overactive bladder. J Fam Pract. 2009 Oct; 58(10 Suppl):S1-11; quiz S12.
Score: 0.326
-
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008 Sep; 180(3):1034-41.
Score: 0.300
-
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology. 2008 Sep; 72(3):488-93.
Score: 0.300
-
Trospium chloride: the European experience. Expert Opin Pharmacother. 2006 Jul; 7(10):1373-80.
Score: 0.260
-
Does urinary urgency drive urinary frequency in overactive bladder? Low Urin Tract Symptoms. 2022 Jul; 14(4):242-247.
Score: 0.192
-
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021 Oct; 13(4):425-434.
Score: 0.182
-
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE). Adv Ther. 2019 08; 36(8):1906-1921.
Score: 0.160
-
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive Bladder. J Urol. 2019 03; 201(3):573-580.
Score: 0.156
-
BK channel regulation by phosphodiesterase type 1: a novel signaling pathway controlling human detrusor smooth muscle function. Am J Physiol Renal Physiol. 2016 05 15; 310(10):F994-9.
Score: 0.127
-
Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2016 06; 35(5):595-600.
Score: 0.119
-
Neurogenic detrusor overactivity is associated with decreased expression and function of the large conductance voltage- and Ca(2+)-activated K(+) channels. PLoS One. 2013; 8(7):e68052.
Score: 0.106
-
The management of overactive bladder syndrome. BMJ. 2012 Apr 17; 344:e2365.
Score: 0.097
-
Suppression of human detrusor smooth muscle excitability and contractility via pharmacological activation of large conductance Ca2+-activated K+ channels. Am J Physiol Cell Physiol. 2012 Jun 01; 302(11):C1632-41.
Score: 0.096
-
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
Score: 0.089
-
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb; 107(4):612-20.
Score: 0.086
-
Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010 Jan; 183(1):234-40.
Score: 0.083
-
Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010 May; 105(9):1276-82.
Score: 0.082
-
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010 May; 105(9):1268-75.
Score: 0.082
-
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009 Sep; 182(3):1055-61.
Score: 0.080
-
Stress incontinence surgery: which operation when? Curr Opin Urol. 2009 Jul; 19(4):362-7.
Score: 0.080
-
Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008 May; 71(5):839-43.
Score: 0.073
-
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19):2319-28.
Score: 0.067
-
SK channel-selective opening by SKA-31 induces hyperpolarization and decreases contractility in human urinary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15; 304(2):R155-63.
Score: 0.025